Circulating cell-free DNA (cf-DNA) is present in human biological fluids, mainly in plasma and serum, originating from cell death, a process that massively takes place during acute myocardial infarction (AMI). In the present study, cf-DNA was assessed by different quantification techniques, in order to determine its levels in patients admitted with AMI. A total of 130 subjects were included in the study: 80 ST elevation myocardial infarction (STEMI) patients and 50 healthy controls. Cf-DNA extracted from plasma was analyzed by: a) Qubit 3.0 with single (ss) and double (ds) stranded DNA assay kits, b) NanoDrop and c) quantitative PCR (qPCR). Cf-DNA levels were recorded elevated in AMI patients compared to those of healthy individuals. Specifically, Qubit 3.0 ss-DNA kit provided the highest cf-DNA concentration values for all the samples analyzed in comparison with ds-DNA assay kit and NanoDrop, approaching the values obtained by qPCR. Cf-DNA augments in massive cell death settings, including AMI, proposing that the quantification of its levels by novel methodologies could contribute to patient diagnosis and clinical management.

循环无细胞DNA（cf-DNA）存在于人类生物体液中，主要存在于血浆和血清中，起源于细胞死亡，这种过程在急性心肌梗死（AMI）中大量发生。在本研究中，通过不同的定量技术对cf-DNA进行了评估，以确定其在AMI患者中的水平。研究共纳入130位受试者：80例ST抬高型心肌梗塞（STEMI）患者和50例健康对照。通过以下方法分析从血浆中提取的Cf-DNA：a）使用单链（ss）和双链（ds）链DNA分析试剂盒的Qubit 3.0，b）NanoDrop和c）定量PCR（qPCR）。据记录，与健康个体相比，AMI患者的Cf-DNA水平升高。具体来说，Qubit 3。与ds-DNA分析试剂盒和NanoDrop相比，0 ss-DNA试剂盒提供了所有分析样品的最高cf-DNA浓度值，接近qPCR获得的值。Cf-DNA增加了包括AMI在内的大规模细胞死亡的情况，这表明通过新颖的方法对其水平进行定量可能有助于患者诊断和临床管理。